Althaia Xarxa Assistencial Universitaria De Manresa Fundacio Privada

This site in Manresa, Spain, has a strong Oncology research portfolio focused on neoplasms and advanced cancer care. The trials are mainly designed to test new treatment options, compare them with current standard care, and improve outcomes for people with hard-to-treat cancers.

• Key studies in breast cancer include hormone receptor-positive, HER2-negative disease, HER2-positive disease, and triple-negative breast cancer, with a focus on better adjuvant and metastatic treatment strategies.
• Research in urothelial cancer and bladder cancer is evaluating whether newer therapies can improve survival and disease control compared with established options.
• Several trials in prostate cancer are exploring ways to delay progression and strengthen treatment effectiveness in both localized and metastatic disease.

Across these studies, the site is contributing to practical questions in cancer care, including whether emerging therapies can extend survival, reduce recurrence, or offer better disease control than current approaches.

A major part of the trial activity centers on breast cancer, especially HR-positive/HER2-negative breast cancer, HER2-positive breast cancer, and triple-negative breast cancer. The research is aimed at improving long-term disease control, reducing recurrence, and finding more effective treatment combinations for both early-stage and advanced disease.

• Studies are examining new approaches for early breast cancer to improve invasive disease-free survival and reduce the chance of relapse.
• Trials in advanced breast cancer are testing targeted therapies and endocrine-based strategies for patients whose disease has already progressed.
• Some research focuses on treatment personalization, including biomarker-guided decisions and strategies for patients at higher risk of recurrence.

At Althaia Xarxa Assistencial Universitaria De Manresa Fundacio Privada, this area reflects a broad effort to refine both standard and newer therapies for different breast cancer subtypes.

The site also supports important research in urothelial cancer and prostate cancer, including muscle-invasive bladder cancer, metastatic urothelial cancer, and high-risk prostate disease. These trials are generally focused on improving survival, slowing progression, and strengthening the effect of treatment before or after surgery.

• In bladder cancer, trials are evaluating new treatment combinations for locally advanced and metastatic disease.
• In prostate cancer, studies are looking at treatment intensification for high-risk localized disease and better control of metastatic disease.
• Some projects examine whether adding targeted or immunotherapy-based approaches can improve outcomes compared with standard treatment alone.

This urologic research reflects a clear goal: to identify more effective options for cancers where durable control remains challenging.

Another active area is Hemic and Lymphatic Diseases, especially multiple myeloma. The trials are designed to improve response quality, deepen remission, and support better long-term disease management in newly diagnosed patients.

• Research in newly diagnosed multiple myeloma is comparing established care with newer combination approaches.
• Studies are also exploring whether treatment strategies can achieve deeper disease responses and better control of residual disease.
• These trials aim to refine first-line therapy for patients who need effective but manageable treatment plans.

This work adds to the site’s broader oncology focus by addressing a blood cancer where treatment depth and durability are especially important.

The research portfolio includes respiratory tract diseases and a wide range of solid tumors, with studies in non-small cell lung cancer, small cell lung cancer, and other advanced cancers. The main purpose is to test new combinations that may improve tumor response and progression-free survival.

• Trials in resectable non-small cell lung cancer are assessing whether treatment before and after surgery can improve cure-related outcomes.
• Studies in small cell lung cancer are looking at maintenance and follow-up strategies to help delay progression.
• Broader advanced solid tumor research is testing novel immunotherapy and targeted therapy combinations across multiple cancer types.

This area shows the site’s involvement in developing more effective cancer treatments across both common and difficult-to-treat tumor types.

Beyond cancer treatment, the site is involved in studies that address symptoms, recovery, and treatment-related side effects. These trials cover digestive system diseases, musculoskeletal diseases, and broader supportive care needs linked to cancer therapy.

• Research includes approaches to reduce chronic postsurgical pain after surgery.
• Some trials aim to prevent surgical complications such as esophagojejunal anastomosis dehiscence after cancer surgery.
• Other studies focus on managing skin toxicities and improving tolerability during cancer treatment.

These studies complement the oncology program by addressing everyday issues that can strongly affect patient comfort and recovery.

The trial landscape at this patient organisation/association also extends into several non-cancer fields, including immune system diseases, respiratory tract diseases, psychiatry and psychology, eye diseases, and metabolic disorders. These studies are aimed at improving symptom control, treatment effectiveness, and quality of life across different conditions.

• Trials in ulcerative colitis and severe asthma are evaluating new treatment options for chronic inflammatory disease.
• Research in major depressive disorder is focused on faster relief of severe symptoms in adolescents.
• Studies in Fuchs endothelial corneal dystrophy and hereditary hemochromatosis are exploring ways to improve function and disease management.

Together, these studies show a diverse research environment that combines oncology leadership with selected trials in other important medical areas.